Usage of Interleukin-6 (IL-6) blockade therapies (tocilizumab and sarilumab) achieve efficacy as therapy for rheumatoid arthritis (RA) in patients at high risk of CVD [31]. Here, IL6 is linked to rheumatoid arthritis.